Abstract: The present invention relates to compounds containing organofluorochlorophosphate anions, the preparation thereof and the use thereof, in particular as ionic liquids.
Type:
Grant
Filed:
December 7, 2007
Date of Patent:
July 3, 2012
Assignee:
Merck Patent GmbH
Inventors:
Nikolai Ignatyev, German Bissky, Helge Willner
Abstract: The invention relates to a method for the one-sided removal of a doped surface layer on rear sides of crystalline silicon solar wafers. In accordance with the object set, doped surface layers should be able to be removed from rear sides of such solar wafers in a cost-effective manner and with a handling which is gentle on the substrate. In addition, the front side should not be modified. In accordance with the invention, an etching gas is directed onto the rear side surface of silicon solar wafers with a plasma atmospheric pressure.
Type:
Grant
Filed:
June 14, 2006
Date of Patent:
July 3, 2012
Assignees:
Fraunhofer-Gesellschaft zur Forderung der Angewandten Forschung E.V., Centrotherm Photovoltaics AG
Inventors:
Moritz Heintze, Rainer Moeller, Harald Wanka, Elena Lopez, Volkmar Hopfe, Ines Dani, Milan Rosina
Abstract: Novel aminoindazolylurea derivatives of the formula I (I), in which R1, R2, R3, R4, R5, X and Y have the meanings indicated in Claim 1, are SGK inhibitors and can be used for the treatment of SGK-induced diseases and complaints, such as diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular diseases and kidney diseases, generally in fibroses and inflammatory processes of any type.
Type:
Grant
Filed:
June 18, 2007
Date of Patent:
June 26, 2012
Assignee:
Merck Patent GmbH
Inventors:
Markus Klein, Rolf Gericke, Norbert Beier, Florian Lang
Abstract: The 17?-cyano-19-nor-androst-4-ene derivatives of the present invention possess gestagenic activity.
Type:
Grant
Filed:
June 11, 2008
Date of Patent:
June 26, 2012
Assignee:
Bayer Pharma AG
Inventors:
Joachim Kuhnke, Jan Huebner, Rolf Bohlmann, Thomas Frenzel, Ulrich Klar, Frederik Menges, Sven Ring, Steffen Borden, Hans-Peter Muhn, Katja Prelle
Abstract: The invention concerns a device for air/water extraction by semi-humid electrostatic collection, comprising a chamber (7) containing a discharge electrode (1) for generating an ion flow from an ionized gas accumulation surrounding the discharge electrode (1) and a counter-electrode (2), an inlet (3) for mixing air and aerosol to be extracted which contains liquid or solid particles, a steam supply tube (8) and an outlet (4) for the cleansed air. The invention is characterized in that the device enables steam to be introduce the steam supply tube (8) in the gap between the discharge electrode (1) and the counter-electrode (2) so as to form a steam sheath (10) enclosing the discharge electrode over its entire length, such that the treated air is not steam-saturated.
Type:
Grant
Filed:
July 24, 2006
Date of Patent:
June 26, 2012
Assignees:
CNRS, Commissariat a l'Energie Atomique
Inventors:
Ernest Galbrun, Jean Luc Achard, Yves Fouillet, Raymond Charles
Abstract: Compounds of the formula (I), in which W, R, R1, R2, R3, R4, R5, R6 and R7 have the meanings indicated in Claim 1, can be employed, inter alia, for the treatment of tumors.
Type:
Grant
Filed:
June 2, 2006
Date of Patent:
June 26, 2012
Assignee:
Merck Patent GmbH
Inventors:
Kai Schiemann, David Bruge, Hans-Peter Buchstaller, Ulrich Emde, Dirk Finsinger, Christiane Amendt, Frank Zenke
Abstract: A polycarbonate polymer includes: a monomer unit represented by a formula (1A) below; and a monomer unit represented by a formula (2). A haze of a solution that is obtained by dissolving the polycarbonate polymer in THF (tetrahydrofuran) at a concentration of 10 mass % is 5% or less (according to JIS K7105, optical path length of 10 mm). In the formula (1A), R and R? each independently represent a hydrogen atom, a halogen atom, an alkyl group having 1 to 12 carbon atoms or a substituted or unsubstituted aryl group having 6 to 12 carbon atoms; n1 is an integer in a range of 2 to 4; and n2 is an integer in a range of 25 to 220; and in the formula (2), Ar represents a divalent aromatic group.
Abstract: This invention relates to novel aryloxypropanolamines. The invention also relates to the pharmaceutically acceptable salts and solvates containing said compounds, methods for the preparation thereof and to respective synthetic intermediates. Said compounds have agonistic activity at ?3 adrenergic receptors and are useful for treatment of ailments influenced by activation of ?3 adrenergic receptors.
Type:
Grant
Filed:
January 22, 2008
Date of Patent:
June 26, 2012
Assignee:
4SC AG
Inventors:
Stefan Tasler, Daniel Vitt, Kristina Wolf, Andrea Aschenbrenner, Peter Ney
Abstract: Disclosed are a dielectrically negative, liquid-crystalline medium which contains a (first) dielectrically negative component (component A), which contains one or more dielectrically negative compounds of formula I and a further (second) dielectrically negative component (component B), and the use thereof in an electro-optical display, particularly in an active-matrix display based on the VA, ECB, PS-VA, FFS or IPS effect, and displays of this type.
Type:
Grant
Filed:
April 5, 2010
Date of Patent:
June 19, 2012
Assignee:
Merck Patent GmbH
Inventors:
Melanie Klasen-Memmer, Axel Jansen, Detlef Pauluth
Abstract: An organic thin film transistor including a substrate having thereon at least three terminals of a gate electrode, a source electrode and a drain electrode, an insulator layer and an organic semiconductor layer, with a current between a source and a drain being controlled upon application of a voltage to the gate electrode, wherein the organic semiconductor layer includes a specified organic compound having an aromatic hydrocarbon group or an aromatic heterocyclic group in the center thereof; and an organic thin film light emitting transistor utilizing an organic thin film transistor, wherein the organic thin film transistor is one in which light emission is obtained utilizing a current flowing between the source and the drain, and the light emission is controlled upon application of a voltage to the gate electrode, and is made high with respect to the response speed and has a large ON/OFF ratio, are provided.
Abstract: Novel 5-cyanothienopyridines of the formula (I), in which R1, R2 and R3 have the meanings indicated in claim 1, are inhibitors of TGF-beta receptor kinase, and can be employed, inter alia, for the treatment of tumors.
Type:
Grant
Filed:
September 19, 2008
Date of Patent:
June 19, 2012
Assignee:
Merck Patent Gesellschaft MIT Beschränkter Haftung
Abstract: The invention relates to a process for the manufacture of enantiomerically enriched or pure compounds of formula I wherein R1, R2, R3, R6, R7 and Q are defined as in claim 1 as well as their crystalline forms for the treatment of proliferative diseases such as cancer.
Type:
Grant
Filed:
May 26, 2007
Date of Patent:
June 12, 2012
Assignee:
Merck Patent Gesellschaft MIT Beschränkter Haftung
Inventors:
Kai Schiemann, Ulrich Emde, Tobias Schlueter, Christoph Saal, Michael Maiwald
Abstract: Process for the continuous hydrogenation of triglyceride containing raw materials in a fixed bed reactor system having several catalyst beds arranged in series and comprising hydrogenation catalyst. The raw material feed, hydrogen containing gas and diluting agent are passed together through the catalyst beds at hydrogenation conditions. The raw material feed stream as well as the stream of hydrogen containing gas are divided into an equal number of different partial streams. These are each passed to one catalyst bed in such a manner that the weight ratio of diluting agent to raw material feed is essentially the same at the entrance of all catalyst beds and does not exceed 4:1. The claimed process is preferably conducted at low temperatures and allows the utilization of existing units due to the low recycle ratio. Further, a sufficient excess of hydrogen is used so that no valuable product is lost through decarb-reactions.
Type:
Grant
Filed:
March 4, 2010
Date of Patent:
June 12, 2012
Assignee:
IFP Energies nouvelles
Inventors:
Detlef Abe, Frank Eschenroder, David Laban, Hartmut Schutter, Laurent Bournay, Thierry Chapus, Nathalie Dupassieux
Abstract: The invention relates to Glycoprotein VI (GPVI), its isolation, purification, and methods for recombinant production. Especially, the invention relates to the use of GPVI, preferably recombinant GPVI, in the treatment of disorders and pathological events correlated directly or indirectly to blood coagulation disorders such as thrombotic and cardiovascular diseases. The extracellular recombinant protein can also be used for establishing screening assays to find potential inhibitors of the membrane bound GPVI in order to inhibit binding of thrombocytes and platelets, respectively, to collagen. Changes in GPIV can be used to monitor platelet age and exposure to thrombotic and cardiovascular diseases.
Abstract: The present invention relates to chemical compounds containing five or more benzene rings arranged in a linear manner and two bridging units between these rings, where at least one of these units represents a —CF2O— bridge. The invention additionally relates to liquid-crystalline media and to high-frequency components comprising these media, in particular antennae, especially for the gigahertz range.
Type:
Grant
Filed:
November 3, 2010
Date of Patent:
June 12, 2012
Assignee:
Merck Patent Gesellschaft mit berschrankter Haftung
Inventors:
Lars Lietzau, Werner Binder, Atsutaka Manabe, Helmut Haensel
Abstract: The present invention relates to a method of producing hydrogen of very high purity from a feed predominantly containing said hydrogen and a minor part of impurities mainly consisting of carbon dioxide, carbon monoxide, methane and heavier hydrocarbons. The purification method by hydrogen adsorption using a desorption stage at a lower pressure than the pressure of the feed, such as a PSA method for example, allows to produce the desorption stream and notably to recover the carbon dioxide under pressure and high-purity hydrogen, with a high yield. These performances are obtained by combining the successive stages of the method according to the invention with the use of a new family of adsorbent whose dynamic capacity at a high desorption pressure is greater than that of conventional adsorbents.
Type:
Grant
Filed:
November 30, 2007
Date of Patent:
June 5, 2012
Assignee:
IFP Energies Nouvelles
Inventors:
Gerhard Pirngruber, Elsa Jolimaitre, Luc Wolff, Damien Leinekugel le Cocq
Abstract: The present invention describes a method for measuring the concentrations of species present at one point of a separation unit functioning in simulated moving bed mode (SMB), using an immersing probe located at one point in the unit or on one of the streams entering or leaving said unit, and a thermocouple located in the vicinity of the immersing probe, in which a Raman spectrum obtained using a laser source functioning at a wavelength of 785 nm is utilized.
Type:
Grant
Filed:
October 19, 2010
Date of Patent:
June 5, 2012
Assignee:
IFP Energies nouvelles
Inventors:
Gerard Hotier, Philibert Leflaive, Mathieu Digne, Philippe Marteau, Jean-Lucien Molle, Michel Leclercq, Sophie Dewally-Morel
Abstract: This present invention disclosed the use of mesoprogestins, a new class of progesterone receptor modulators (PRMs), for the treatment and prevention of benign hormone dependent gynecological disorders: a) for the treatment of gynecological disorder such as endometriosis, uterine fibroids, postoperative peritoneal adhesions, dysfunctional bleeding (metrorrhagia, menorrhagia) and dysmenorrhea; b) for the prevention of gynecological disorders such as postoperative, peritoneal adhesions, dysfunctional uterine bleeding (metrorrhagia, menorrhagia) and dysmenorrhea; and c) a method of treatment and prevention of the above mentioned disorders in a female, preferably in a human female, in need of treatment or prevention of one or more of these disorders, with an effective amount of a mesoprogestin. Mesoprogestins are defined as compounds possessing both agonistic and antagonistic activities at the progesterone receptor (PR) in vivo.
Type:
Grant
Filed:
August 31, 2000
Date of Patent:
June 5, 2012
Assignee:
Bayer Pharma AG
Inventors:
Kristof Chwalisz, Walter Elger, Gerd Shubert
Abstract: The invention relates in particular to a housing for protecting and masking a toilet bowl whose top part is provided with a peripheral inwardly folded edge which delimits with the bowl a water distribution channel and which is characterized in that it consists of a body (30) and a cover part (32) which is open in the center thereof, is independent of said body (30) and is arrangeable on the body in such a way that it covers the peripheral edge (11) of the bowl, wherein the body (30) is provided with an anchoring part (5) interacting with the cover part (32) and said anchoring and cover (32) parts comprise complementarily shaped connecting means (51, 330).